|
1
|
Wang QL, Xie SH, Wahlin K and Lagergren J:
Global time trends in the incidence of esophageal squamous cell
carcinoma. Clin Epidemiol. 10:717–728. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8)(S4-S66)2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kohler BA, Ward E, McCarthy BJ, Schymura
MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards
BK: Annual report to the nation on the status of cancer, 1975-2007,
featuring tumors of the brain and other nervous system. J Natl
Cancer Inst. 103:714–736. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Glozak MA and Seto E: Histone deacetylases
and cancer. Oncogene. 26:5420–5432. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hull EE, Montgomery MR and Leyva KJ: HDAC
inhibitors as epigenetic regulators of the immune system: Impacts
on cancer therapy and inflammatory diseases. Biomed Res Int.
2016(8797206)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yamagoe S, Kanno T, Kanno Y, Sasaki S,
Siegel RM, Lenardo MJ, Humphrey G, Wang Y, Nakatani Y, Howard BH
and Ozato K: Interaction of histone acetylases and deacetylases in
vivo. Mol Cell Biol. 23:1025–1033. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cao LL, Yue Z, Liu L, Pei L, Yin Y, Qin L,
Zhao J, Liu H, Wang H and Jia M: The expression of histone
deacetylase HDAC1 correlates with the progression and prognosis of
gastrointestinal malignancy. Oncotarget. 8:39241–39253.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nemati M, Ajami N, Estiar MA, Rezapour S,
Gavgani RR, Hashemzadeh S, Kafil HS and Sakhinia E: Deregulated
expression of HDAC3 in colorectal cancer and its clinical
significance. Adv Clin Exp Med. 27:305–311. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba
H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T and Sugimachi K:
Histone H4 acetylation and histone deacetylase 1 expression in
esophageal squamous cell carcinoma. Oncol Rep. 10:333–338.
2003.PubMed/NCBI
|
|
11
|
Micheli L, D'Andrea G, Leonardi L and
Tirone F: HDAC1, HDAC4, and HDAC9 bind to PC3/Tis21/Btg2 and are
required for its inhibition of cell cycle progression and cyclin D1
expression. J Cell Physiol. 232:1696–1707. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nakashima H, Nguyen T and Chiocca EA:
Combining HDAC inhibitors with oncolytic virotherapy for cancer
therapy. Oncolytic Virother. 4:183–191. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yoon S and Eom GH: HDAC and HDAC
inhibitor: From cancer to cardiovascular diseases. Chonnam Med J.
52:1–11. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Thangaraju M, Carswell KN, Prasad PD and
Ganapathy V: Colon cancer cells maintain low levels of pyruvate to
avoid cell mortality caused by inhibition of HDAC1/HDAC3. Biochem
J. 417:379–389. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu C, Liu L, Shan J, Shen J, Xu Y, Zhang
Q, Yang Z, Wu L, Xia F, Bie P, et al: Histone deacetylase 3
participates in self-renewal of liver cancer stem cells through
histone modification. Cancer Lett. 339:60–69. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xu G, Zhu H, Zhang M and Xu J: Histone
deacetylase 3 is associated with gastric cancer cell growth via the
miR-454-mediated targeting of CHD5. Int J Mol Med. 41:155–163.
2018. View Article : Google Scholar
|
|
17
|
Taunton J, Hassig CA and Schreiber SL: A
mammalian histone deacetylase related to the yeast transcriptional
regulator Rpd3p. Science. 272:408–411. 1996.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen L, Wang C, Luo J, Su W, Li M, Zhao N,
Lyu W, Attaran H, He Y, Ding H and He H: Histone deacetylase 1
plays an acetylation-independent role in influenza a virus
replication. Front Immunol. 8(1757)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Datta M, Staszewski O, Raschi E, Frosch M,
Hagemeyer N, Tay TL, Blank T, Kreutzfeldt M, Merkler D,
Ziegler-Waldkirch S, et al: Histone deacetylases 1 and 2 regulate
microglia function during development, homeostasis, and
neurodegeneration in a context-dependent manner. Immunity.
48:514–529. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qiao W, Liu H, Liu R, Liu Q, Zhang T, Guo
W, Li P and Deng M: Prognostic and clinical significance of histone
deacetylase 1 expression in breast cancer: A meta-analysis. Clin
Chim Acta. 483:209–215. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sekhavat A, Sun JM and Davie JR:
Competitive inhibition of histone deacetylase activity by
trichostatin A and butyrate. Biochem Cell Biol. 85:751–758.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Burdelski C, Ruge OM, Melling N, Koop C,
Simon R, Steurer S, Sauter G, Kluth M, Hube-Magg C, Minner S, et
al: HDAC1 overexpression independently predicts biochemical
recurrence and is associated with rapid tumor cell proliferation
and genomic instability in prostate cancer. Exp Mol Pathol.
98:419–426. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang BH, Laban M, Leung CH, Lee L, Lee
CK, Salto-Tellez M, Raju GC and Hooi SC: Inhibition of histone
deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression,
independent of histone deacetylase 1. Cell Death Differ.
12:395–404. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mutze K, Langer R, Becker K, Ott K,
Novotny A, Luber B, Hapfelmeier A, Gottlicher M, Hofler H and
Keller G: Histone deacetylase (HDAC) 1 and 2 expression and
chemotherapy in gastric cancer. Ann Surg Oncol. 17:3336–3343.
2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shinke G, Yamada D, Eguchi H, Iwagami Y,
Asaoka T, Noda T, Wada H, Kawamoto K, Gotoh K, Kobayashi S, et al:
Role of histone deacetylase 1 in distant metastasis of pancreatic
ductal cancer. Cancer Sci. 109:2520–2531. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang Z, Yamashita H, Toyama T, Sugiura H,
Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S and Iwase H:
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the
breast. Breast Cancer Res Treat. 94:11–16. 2005.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang H, Kohashi K, Yoshizumi T, Okumura Y,
Tanaka Y, Shimokawa M, Iwasaki T, Aishima S, Maehara Y and Oda Y:
Co-expression of SALL4 with HDAC1 and/or HDAC2 is associated with
underexpression of PTEN and poor prognosis in patients with
hepatocellular carcinoma. Hum Pathol. 64:69–75. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhong L, Zhou S, Tong R, Shi J, Bai L, Zhu
Y, Duan X, Liu W, Bao J, Su L and Peng Q: Preclinical assessment of
histone deacetylase inhibitor quisinostat as a therapeutic agent
against esophageal squamous cell carcinoma. Invest New Drugs.
37:616–624. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Miyashita T, Tajima H, Munemoto M, Shah
FA, Harmon JW, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S,
et al: Impact of histone deacetylase 1 and metastasis-associated
gene 1 expression in esophageal carcinogenesis. Oncol Lett.
8:758–764. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Langer R, Mutze K, Becker K, Feith M, Ott
K, Hofler H and Keller G: Expression of class I histone
deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: An
immunohistochemical study. J Clin Pathol. 63:994–998.
2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xu J, Lv H, Zhang B, Xu F, Zhu H, Chen B,
Zhu C and Shen J: miR-30b-5p acts as a tumor suppressor microRNA in
esophageal squamous cell carcinoma. J Thorac Dis. 11:3015–3029.
2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kiweler N, Brill B, Wirth M, Breuksch I,
Laguna T, Dietrich C, Strand S, Schneider G, Groner B, Butter F, et
al: The histone deacetylases HDAC1 and HDAC2 are required for the
growth and survival of renal carcinoma cells. Arch Toxicol.
92:2227–2243. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fritsche P, Seidler B, Schuler S, Schnieke
A, Gottlicher M, Schmid RM, Saur D and Schneider G: HDAC2 mediates
therapeutic resistance of pancreatic cancer cells via the BH3-only
protein NOXA. Gut. 58:1399–1409. 2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Witt O, Deubzer HE, Milde T and Oehme I:
HDAC family: What are the cancer relevant targets? Cancer Lett.
277:8–21. 2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Barnes PJ: Histone deacetylase-2 and
airway disease. Ther Adv Respir Dis. 3:235–243. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yao H and Rahman I: Role of histone
deacetylase 2 in epigenetics and cellular senescence: Implications
in lung inflammaging and COPD. Am J Physiol Lung Cell Mol Physiol.
303(L557-L566)2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Brodie SA, Li G, El-Kommos A, Kang H,
Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR,
et al: Class I HDACs are mediators of smoke carcinogen-induced
stabilization of DNMT1 and serve as promising targets for
chemoprevention of lung cancer. Cancer Prev Res (Phila). 7:351–361.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Han Y, Zhang Y, Yang LH, Mi XY, Dai SD, Li
QC, Xu HT, Yu JH, Li G, Zhao J, et al: X-radiation inhibits histone
deacetylase 1 and 2, upregulates Axin expression and induces
apoptosis in non-small cell lung cancer. Radiat Oncol.
7(183)2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ,
Xie HJ, Chang YG, Kim MG, Park H, Lee JY and Nam SW: HDAC2
overexpression confers oncogenic potential to human lung cancer
cells by deregulating expression of apoptosis and cell cycle
proteins. J Cell Biochem. 113:2167–2177. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Huang R, Langdon SP, Tse M, Mullen P, Um
IH, Faratian D and Harrison DJ: The role of HDAC2 in chromatin
remodelling and response to chemotherapy in ovarian cancer.
Oncotarget. 7:4695–4711. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang F, Qi Y, Li X, He W, Fan QX and Zong
H: HDAC inhibitor trichostatin A suppresses esophageal squamous
cell carcinoma metastasis through HADC2 reduced MMP-2/9. Clin
Invest Med. 36(E87-E94)2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li S, Wang F, Qu Y, Chen X, Gao M, Yang J,
Zhang D, Zhang N, Li W and Liu H: HDAC2 regulates cell
proliferation, cell cycle progression and cell apoptosis in
esophageal squamous cell carcinoma EC9706 cells. Oncol Lett.
13:403–409. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Göder A, Emmerich C, Nikolova T, Kiweler
N, Schreiber M, Kühl T, Imhof D, Christmann M, Heinzel T, Schneider
G and Krämer OH: HDAC1 and HDAC2 integrate checkpoint kinase
phosphorylation and cell fate through the phosphatase-2A subunit
PR130. Nat Commun. 9(764)2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bhaskara S, Knutson SK, Jiang G,
Chandrasekharan MB, Wilson AJ, Zheng S, Yenamandra A, Locke K, Yuan
JL, Bonine-Summers AR, et al: Hdac3 is essential for the
maintenance of chromatin structure and genome stability. Cancer
Cell. 18:436–447. 2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li J, Jin W, Wang J, Nawaz Z, Liu JM, Qin
J and Wong J: Both corepressor proteins SMRT and N-CoR exist in
large protein complexes containing HDAC3. EMBO J. 19:4342–4350.
2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Weichert W, Röske A, Niesporek S, Noske A,
Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T and Denkert
C: Class I histone deacetylase expression has independent
prognostic impact in human colorectal cancer: Specific role of
class I histone deacetylases in vitro and in vivo. Clin Cancer Res.
14:1669–1677. 2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Weichert W, Röske A, Gekeler V, Beckers T,
Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of
patterns of class I histone deacetylase expression with patient
prognosis in gastric cancer: A retrospective analysis. Lancet
Oncol. 9:139–148. 2008.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hayashi A, Horiuchi A, Kikuchi N, Hayashi
T, Fuseya C, Suzuki A, Konishi I and Shiozawa T: Type-specific
roles of histone deacetylase (HDAC) overexpression in ovarian
carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates
cell migration with downregulation of E-cadherin. Int J Cancer.
127:1332–1346. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Minamiya Y, Ono T, Saito H, Takahashi N,
Ito M, Motoyama S and Ogawa J: Strong expression of HDAC3
correlates with a poor prognosis in patients with adenocarcinoma of
the lung. Tumour Biol. 31:533–539. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang
H and Wang L and Wang L: Aberrant expression of nuclear HDAC3 and
cytoplasmic CDH1 predict a poor prognosis for patients with
pancreatic cancer. Oncotarget. 7:16505–16516. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Yao Z, Xu M and Zhou Z: The role of
Histone deacetylase 3 in esophageal squamous cell carcinoma
pathogenesis. Chin J Dig. 32:760–762. 2012.(In Chinese). PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ahrens TD, Timme S, Hoeppner J, Ostendorp
J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M and
Lassmann S: Selective inhibition of esophageal cancer cells by
combination of HDAC inhibitors and Azacytidine. Epigenetics.
10:431–445. 2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Kano M, Yamada S, Hoshino I, Murakami K,
Akutsu Y, Sakata H, Nishimori T, Usui A, Miyazawa Y, Kamada T, et
al: Effects of carbon-ion radiotherapy combined with a novel
histone deacetylase inhibitor, cyclic hydroxamic-acid-containing
peptide 31 in human esophageal squamous cell carcinoma. Anticancer
Res. 29:4433–4438. 2009.PubMed/NCBI
|
|
54
|
Hoshino I, Matsubara H, Akutsu Y,
Nishimori T, Yoneyama Y, Murakami K, Sakata H, Matsushita K,
Komatsu A, Brooks R and Ochiai T: Role of histone deacetylase
inhibitor in adenovirus-mediated p53 gene therapy in esophageal
cancer. Anticancer Res. 28:665–671. 2008.PubMed/NCBI
|
